Vertex announces extended long-term reimbursement agreement with NHS England for access to cystic fibrosis medicines Kaftrio, Symkevi and Orkambi

20 June 2024 - Agreement includes access to any future licence extensions. ...

Read more →

NICE enables access to first treatment that targets the underlying pathophysiology of rare disease X-linked hypophosphataemia in adults

21 June 2024 - Kyowa Kirin is delighted by the decision made today by NICE to recommend Crysvita for the treatment ...

Read more →

Tafamidis meglumine for the treatment of patients with transthyretin amyloidosis with cardiomyopathy (final guidance)

19 June 2024 - NICE has published final evidence-based recommendations on the use of tafamidis meglumine (Vyndaqel) for the treatment ...

Read more →

House dust mite allergen for the treatment of patients with allergic rhinitis and allergic asthma caused by house dust mites (review of TA834)

13 June 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...

Read more →

Baricitinib for the treatment of patients with juvenile idiopathic arthritis

13 June 2024 - NICE is unable to make a recommendation on the use in the NHS of baricitinib (Olumiant) for ...

Read more →

Voxelotor for the treatment of patients with haemolytic anaemia caused by sickle cell disease

12 June 2024 - NICE has published final evidence-based recommendations on the use of voxelotor (Oxbryta) for the treatment of ...

Read more →

Trifluridine with tipiracil hydrochloride in combination with bevacizumab for the treatment of patients with metastatic colorectal cancer after two systemic treatments

6 June 2024 - The Department of Health and Social Care has asked the NICE to produce guidance on the ...

Read more →

Danicopan in combination with ravulizumab or eculizumab for the treatment of patients with paroxysmal nocturnal haemoglobinuria

29 May 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...

Read more →

Ivosidenib in combination with azacitidine for the first-line treatment of patients with IDH1 R132 mutation positive acute myeloid leukaemia (final guidance)

5 June 2024 - NICE has published final evidence-based guidance on the use of ivosidenib with azacitidine in the NHS ...

Read more →

Nivolumab for the adjuvant treatment of patients 12 years and older with completely resected melanoma at high risk of recurrence

5 June 2024 - NICE is unable to make a recommendation on the use of nivolumab (Opdivo) for the adjuvant treatment ...

Read more →

Mounjaro is second obesity drug to be approved for use in England

4 June 2024 - Those with BMI of at least 35 kg.m2 and a co-morbidity can now be prescribed tirzepatide and ...

Read more →

Zanubrutinib in combination with obinutuzumab for the treatment of patients with relapsed or refractory B-cell follicular lymphoma after two or more treatments

28 May 2024 - NICE is unable to make a recommendation on the use of zanubrutinib (Brukinsa) in combination with obinutuzumab ...

Read more →

Trastuzumab deruxtecan for the treatment of patients with advanced HER2 mutation positive non-small-cell lung cancer after platinum-based chemotherapy

29 May 2024 - NICE is unable to make a recommendation on the use of trastuzumab deruxtecan (Enhertu) for the treatment ...

Read more →

NICE and NHS England announce plan to enable innovative tech to be adopted quicker

23 May 2024 - NHS patients in England will benefit from faster access to the most innovative and cutting-edge medical technologies ...

Read more →

Sirolimus for the treatment of patients with facial angiofibroma caused by tuberous sclerosis complex

22 May 2024 - NICE is unable to make a recommendation on the use of sirolimus (Hyftor) for the treatment of ...

Read more →